These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 35729252)

  • 1. Sustained effects of single doses of classical psychedelics in humans.
    Knudsen GM
    Neuropsychopharmacology; 2023 Jan; 48(1):145-150. PubMed ID: 35729252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psilocybin and Other Classic Psychedelics in Depression.
    Nutt DJ; Peill JM; Weiss B; Godfrey K; Carhart-Harris RL; Erritzoe D
    Curr Top Behav Neurosci; 2024; 66():149-174. PubMed ID: 37955822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards an understanding of psychedelic-induced neuroplasticity.
    Calder AE; Hasler G
    Neuropsychopharmacology; 2023 Jan; 48(1):104-112. PubMed ID: 36123427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Psychedelics in Treatment-Resistant Depression.
    Kamal S; Jha MK; Radhakrishnan R
    Psychiatr Clin North Am; 2023 Jun; 46(2):291-305. PubMed ID: 37149346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
    Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
    Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychedelia: The interplay of music and psychedelics.
    Jerotic K; Vuust P; Kringelbach ML
    Ann N Y Acad Sci; 2024 Jan; 1531(1):12-28. PubMed ID: 37983198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis.
    Leger RF; Unterwald EM
    J Psychopharmacol; 2022 Jan; 36(1):20-30. PubMed ID: 34519567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
    Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A
    Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychedelic drugs for psychiatric disorders.
    da Costa SC; Oesterle T; Rummans TA; Richelson E; Gold M
    J Neurol Sci; 2022 Sep; 440():120332. PubMed ID: 35841696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Contribution of serotonin 5-HT
    Ibi D
    Nihon Yakurigaku Zasshi; 2023 May; 158(3):229-232. PubMed ID: 36990794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Therapeutic Potential of Psilocybin.
    Lowe H; Toyang N; Steele B; Valentine H; Grant J; Ali A; Ngwa W; Gordon L
    Molecules; 2021 May; 26(10):. PubMed ID: 34063505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psilocybin--summary of knowledge and new perspectives.
    Tylš F; Páleníček T; Horáček J
    Eur Neuropsychopharmacol; 2014 Mar; 24(3):342-56. PubMed ID: 24444771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis.
    Yao Y; Guo D; Lu TS; Liu FL; Huang SH; Diao MQ; Li SX; Zhang XJ; Kosten TR; Shi J; Bao YP; Lu L; Han Y
    Psychiatry Res; 2024 May; 335():115886. PubMed ID: 38574699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human behavioral pharmacology of psychedelics.
    Strickland JC; Johnson MW
    Adv Pharmacol; 2022; 93():105-132. PubMed ID: 35341564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychedelics and Personality.
    Aixalà M; Dos Santos RG; Hallak JEC; Bouso JC
    ACS Chem Neurosci; 2018 Oct; 9(10):2304-2306. PubMed ID: 29863323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms.
    Skosnik PD; Sloshower J; Safi-Aghdam H; Pathania S; Syed S; Pittman B; D'Souza DC
    J Psychopharmacol; 2023 Jul; 37(7):687-697. PubMed ID: 37392016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders.
    Wulff AB; Nichols CD; Thompson SM
    Neuropharmacology; 2023 Jun; 231():109504. PubMed ID: 36921889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
    Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis.
    Goldberg SB; Shechet B; Nicholas CR; Ng CW; Deole G; Chen Z; Raison CL
    Psychol Med; 2020 Dec; 50(16):2655-2666. PubMed ID: 33143790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Classical psychedelics for the treatment of depression and anxiety: A systematic review.
    Muttoni S; Ardissino M; John C
    J Affect Disord; 2019 Nov; 258():11-24. PubMed ID: 31382100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.